VIKTORIA-1 shows gedatolisib maintained strong PFS benefit over alpelisib in PIK3CA-mutant HR+/HER2− breast cancer, including ...

Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical ...

In BV2 microglial cells, esketamine suppressed lipopolysaccharide-induced M1 polarization by selectively acting on the NMDAR2A receptor subtype and activating mTOR and BDNF-TrkB signaling.

Faeth Therapeutics announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled ?Characterising the efficacy of ...

A query audit of 26 named KEGG signaling pathways in extracellular-vesicle research found that only three PubMed retrievals ...

Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (BMV:RVMD) with an Outperform recommendation. Revolution Medicines, Inc., based in the United States, ...

Poster will characterize the efficacy of PIKTOR as a monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors in preclinical models of breast cancer; Poster ...

Kazia Therapeutics (KZIA) stock gains new Buy from Gueggenheim, based on company's lead asset paxalisib, following a similar view from Leerink this week. Read more here.

Researchers follow the children of centenarians to see what longevity and disease-resistance traits they may inherit. The ...

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions ...

MONARCH shows median OS of 32.1 vs 24.6 months with abemaciclib after prior CDK4/6 therapy, but the survival difference was ...